W. Mark Saltzman
Website:Saltzman Research Group
- Ph.D., Harvard/MIT Division of Health Science and Technology
- S.M., Massachusetts Institute of Technology
- B.S., Iowa State University
Saltzman's research is motivated by the desire to create safer and more effective medical and surgical therapy. He focuses on tissue engineering and on creating better methods for drug delivery. His group has developed technology based on the use of bio-compatible polymeric materials for the controlled delivery of drugs, proteins, and genes. They have also developed new polymeric materials that influence the growth and assembly of tissues. However, even better than treating disease is to prevent disease from occurring in the first place. Saltzman's intent, therefore, is to develop the most economical, transportable, and accessible methods for disease prevention.
Saltzman is also committed to training a new generation of chemical and biomedical engineers. He believes in providing a stimulating and collaborative environment that promotes the free exchange of ideas and encourages creative blending of technology and modern biological science.
Selected Awards & Honors:
- Elected Member, National Academy of Medicine (formerly Institute of Medicine) (2014)
- Mines Medalist, South Dakota School of Mines (2014)
- Fellow, National Academy of Inventors (2013)
- Fellow, Biomedical Engineering Society (2010)
- Sheffield Teaching Prize, Yale University (2009)
- Paper selected as one of top 25 published over past 25 years in Biomaterials (2006)
- Distinguished Lecturer Award, Biomedical Engineering Society (2004)
- BP Amoco/H.Laurence Fuller Chair in Chemical Engineering at Cornell (2001)
- Britton Chance Distinguished Lecturer in Engineering and Medicine, at the University of Pennsylvania (2000)
- Professional Progress in Engineering Award from Iowa State University (2000)
- Member, Surgery & Bioengineering Study Section (NIH) (1999)
- Richard Tucker Excellence in Teaching Award (Cornell) (1999)
- Fellow, American Institute for Medical and Biological Engineering (1997)
- Controlled Release Society Young Investigator Award (1996)
- Allan C. Davis Medal as Maryland's Outstanding Young Engineer (1995)
- Distinguished Faculty Award for Excellence in Undergraduate Education (Johns Hopkins) (1995)
- Camille and Henry Dreyfus Foundation Teacher-Scholar Award. (1990)
- McNeer, NA, Chin JY, Schleifman EB, Fields RJ, Glazer PM, and Saltzman WM. Nanoparticles deliver triplex-forming PNA for site-specific genomic recombination in CD34+ human hematopoietic progenitors. Molecular Therapy 19:172-180 (2011). PMCID: PMC3017438.
- Zhou J, Liu J, Cheng CJ, Patel T, Weller C, Piepmeier JM, Jiang Z, and Saltzman WM. Biodegradable poly(amine-co-ester) terpolymers for targeted gene delivery, Nature Materials 11:82-90 (2012). PMCID: PMC4180913.
- Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman WM, Slack FJ. Nanoparticle-based therapy in an in vivo miR-155-dependent mouse model of lymphoma, Proceedings of the National Academy of Sciences 109 (26) E1695-E1704 (2012). PMCID: PMC3387084.
- Zhou J, Patel TR, Sirianni RW, Strohbehn G, Zheng MQ, Duong N, Schafbauer T, Huttner AJ, Huang Y, Carson RE, Zhang Y, Sullivan DJ, Piepmeier JM, and Saltzman WM. Highly penetrative nanocarriers loaded with drugs targeted to resistant cells improve treatment of glioblastoma, Proceedings of the National Academy of Sciences, 110 (29): 11751-11756 (2013). PMCID: PMC3718184.
- Devalliere J, Chang WG, Andrejecsk JW, Cheng CJ, Jane-wit D, Saltzman WM, and Pober JS. Sustained delivery of pro-angiogenic microRNA-132 by nanoparticle transfection improves endothelial cell transplantation, FASEB Journal 28(2): 908-922 (2014). PMCID: PMC3898640.
- Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM, Saltzman WM, and Slack FJ. MicroRNA silencing for cancer therapy targeted to the tumor microenvironment, Nature 518:107-110 (2015). PMCID: PMC4367962.
- McNeer NA, Anandalingam K, Quijano E, Fields RJ, Caputo C, Glazer PM, Saltzman WM, and Egan ME. In vivo and in vitro correction of F508del CFTR using nanoparticles with triplex-forming PNAs in airway epithelia. Nature Communications 6:6952 (2015). PMCID: in process.
- Abrahimi P, Chang WG, Kluger MS, Qyang Y, Tellides G, Saltzman WM, and Pober JS. Efficient gene disruption in cultured primary human endothelial cells by CRISPR/Cas9, Circulation Research, 117: 121-128 (2015). PCMID: in process.
- Drug Delivery: Engineering Principles for Drug Therapy, 2001, Published by Oxford University Press.
- Tissue Engineering: Engineering principles for the design of replacement organs and tissues, 2004, Published by Oxford University Press.
- Biomedical Engineering: Bridging Medicine and Technology, 2009, Published by Cambridge University Press.